• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . CD8 + T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses

tetano

Editor, Senior Moderator
Immunity


. 2021 Apr 13;S1074-7613(21)00168-0.
doi: 10.1016/j.immuni.2021.04.006. Online ahead of print.
CD8 [SUP]+[/SUP] T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses


Katie E Lineburg[SUP] 1 [/SUP], Emma J Grant[SUP] 2 [/SUP], Srividhya Swaminathan[SUP] 3 [/SUP], Demetra S M Chatzileontiadou[SUP] 2 [/SUP], Christopher Szeto[SUP] 2 [/SUP], Hannah Sloane[SUP] 2 [/SUP], Archana Panikkar[SUP] 1 [/SUP], Jyothy Raju[SUP] 1 [/SUP], Pauline Crooks[SUP] 1 [/SUP], Sweera Rehan[SUP] 1 [/SUP], Andrea T Nguyen[SUP] 2 [/SUP], Lea Lekieffre[SUP] 1 [/SUP], Michelle A Neller[SUP] 1 [/SUP], Zhen Wei Marcus Tong[SUP] 4 [/SUP], Dhilshan Jayasinghe[SUP] 2 [/SUP], Keng Yih Chew[SUP] 4 [/SUP], Christian A Lobos[SUP] 2 [/SUP], Hanim Halim[SUP] 5 [/SUP], Jacqueline M Burrows[SUP] 1 [/SUP], Alan Riboldi-Tunnicliffe[SUP] 6 [/SUP], Weisan Chen[SUP] 7 [/SUP], Lloyd D'Orsogna[SUP] 8 [/SUP], Rajiv Khanna[SUP] 1 [/SUP], Kirsty R Short[SUP] 9 [/SUP], Corey Smith[SUP] 10 [/SUP], Stephanie Gras[SUP] 11 [/SUP]



Affiliations

Abstract

Efforts are being made worldwide to understand the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, including the impact of T cell immunity and cross-recognition with seasonal coronaviruses. Screening of SARS-CoV-2 peptide pools revealed that the nucleocapsid (N) protein induced an immunodominant response in HLA-B7[SUP]+[/SUP] COVID-19-recovered individuals that was also detectable in unexposed donors. A single N-encoded epitope that was highly conserved across circulating coronaviruses drove this immunodominant response. In vitro peptide stimulation and crystal structure analyses revealed T cell-mediated cross-reactivity toward circulating OC43 and HKU-1 betacoronaviruses but not 229E or NL63 alphacoronaviruses because of different peptide conformations. T cell receptor (TCR) sequencing indicated that cross-reactivity was driven by private TCR repertoires with a bias for TRBV27 and a long CDR3? loop. Our findings demonstrate the basis of selective T cell cross-reactivity for an immunodominant SARS-CoV-2 epitope and its homologs from seasonal coronaviruses, suggesting long-lasting protective immunity.

Keywords: CD8(+) T cell; HLA; SARS-CoV-2; cross-reactivity; immune response; immunodominant epitope; seasonal coronaviruses.
 
Back
Top Bottom